Hologic, Inc. (HOLX)

FairStock Score: 51/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I see Hologic as a solid but not extraordinary healthcare business. It sells diagnostics, breast health, GYN surgical, and skeletal health products, which gives it a clinically entrenched franchise, though the data do not give me a hard moat measure. The latest period-labeled filing is the quarter labeled 2025-Q4: revenue of $1.0B, net income of $179.1M, and a 17.09% margin. That is real profitability, and trailing free cash flow of $957.2M supports a 5.7% FCF yield, a FairStock calculation. The balance sheet looks tolerable, with debt/equity of 0.48 and an Altman Z-score of 3.70, also a FairStock calculation. But the price is demanding. At the 2026-04-07 close of $76.01, FairStock shows a P/E of 31.54 and P/B of 3.23. Returns are only moderate: ROE 10.86% and ROCE 7.43%, both FairStock calculations, while the Piotroski F-score is 6/9. The supplied growth indicators are soft, and filed period-labeled history is thin—only the 2025-Q4 quarter stands out in the data. FairStock's Graham Number is $35.70, with a stated margin of safety of -112.91%, so the price is far above that conservative accounting yardstick. The 52-week range is $73.86-$76.07, placing the close near the high. The FairStock Score is 51/100. I see cash generation and a useful healthcare niche, but the valuation already assumes better growth and profitability than the figures show.

In plain English: Hologic makes medical tests, breast imaging systems, and surgical products, mainly for women’s health. It is profitable and produces cash, but sales are growing slowly and profit has recently fallen. At the recent $76.01 close, the shares look expensive compared with the company’s profits and accounting value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-04-07 close · note generated 2026-11-01 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer